XK and influenza: Therapeutic choices to control influenza infection are currently limited to two classes of FDA-approved antivirals targeting either the viral M2 ion channel (amantadine, rimantadine) [77,78,79] or the sialidase active site of NA (oseltamivir, zanamivir) [80].